睿智医药所属申万行业为：医药生物-医疗服务-医疗研发外包。所属概念板块包括：生物医药、阿尔茨 海默、创新药、抗癌治癌、AI医药等。 截至12月20日，睿智医药股东户数3.86万，较上期减少1.92%；人均流通股12307股，较上期增加 1.96%。2025年1月-9月，睿智医药实现营业收入8.17亿元，同比增长13.68%；归母净利润709.13万元， 同比增长111.50%。 分红方面，睿智医药A股上市后累计派现1.80亿元。近三年，累计派现0.00元。 机构持仓方面，截止2025年9月30日，睿智医药十大流通股东中，香港中央结算有限公司位居第四大流 通股东，持股2432.58万股，相比上期减少6100.00股。 1月7日，睿智医药盘中上涨2.09%，截至09:54，报10.25元/股，成交4279.82万元，换手率0.89%，总市 值51.04亿元。 资金流向方面，主力资金净流入310.43万元，大单买入1059.00万元，占比24.74%，卖出748.56万元，占 比17.49%。 睿智医药今年以来股价涨7.22%，近5个交易日涨6.55%，近20日涨2.60%，近60日跌9.29%。 资料显示，睿智医 ...

Core Insights - RuiZhi Pharmaceutical is a leading pharmaceutical research and production outsourcing service provider in China, established on January 26, 2000, and listed on the Shenzhen Stock Exchange on December 22, 2010 [1] Financial Performance - For Q3 2025, RuiZhi Pharmaceutical reported revenue of 817 million yuan, ranking 13th among 29 companies in the industry. The top company, WuXi AppTec, had revenue of 32.857 billion yuan, while the industry average was 2.547 billion yuan [2] - The main business revenue from pharmaceutical research and production outsourcing services was 529 million yuan, accounting for 99.06% of total revenue. Other revenues included 2.7823 million yuan from prebiotic products (0.52%), 1.846 million yuan from rental income (0.35%), and 397,300 yuan from other sources (0.07%) [2] - The net profit for the same period was 7.1621 million yuan, ranking 23rd in the industry. The leading company, WuXi AppTec, reported a net profit of 12.206 billion yuan, with the industry average at 585 million yuan [2] Financial Ratios - As of Q3 2025, RuiZhi Pharmaceutical's debt-to-asset ratio was 35.77%, higher than the previous year's 35.56% and above the industry average of 22.79% [3] - The gross profit margin for the period was 27.55%, an increase from 19.22% in the previous year, but still below the industry average of 37.70% [3] Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 4.70% to 42,600, while the average number of circulating A-shares held per shareholder increased by 4.94% to 11,200 [5] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited ranked as the fourth largest, holding 24.3258 million shares, a decrease of 6,100 shares from the previous period [5] Leadership Compensation - The chairman, Hu Ruilian, received a salary of 1.2011 million yuan in 2024. He holds multiple positions, including CEO and director of RuiZhi Pharmaceutical [4]

Core Insights - The stock of Ruizhi Pharmaceutical experienced a decline of 0.78% on September 30, with a trading volume of 119 million yuan [1] - The company reported a net financing outflow of 13.11 million yuan on the same day, with a total financing and securities balance of 203 million yuan [1][2] - For the first half of 2025, Ruizhi Pharmaceutical achieved a revenue of 534 million yuan, representing a year-on-year growth of 14.75%, and a net profit of 25.38 million yuan, up 140.35% year-on-year [2] Financing and Trading Activity - On September 30, the financing buy-in amount for Ruizhi Pharmaceutical was 9.17 million yuan, while the financing repayment was 22.28 million yuan, resulting in a net financing buy-in of -13.11 million yuan [1] - The current financing balance of 203 million yuan accounts for 3.58% of the circulating market value, which is above the 70th percentile of the past year [1] - The company had a securities lending balance of 4,200 shares, with a total value of 47,900 yuan, which is below the 20th percentile of the past year [1] Shareholder and Dividend Information - As of September 20, the number of shareholders for Ruizhi Pharmaceutical was 44,700, a decrease of 5.99% from the previous period, while the average circulating shares per person increased by 6.37% to 10,626 shares [2] - Since its A-share listing, the company has distributed a total of 180 million yuan in dividends, with no dividends paid in the last three years [3] - As of June 30, 2025, Hong Kong Central Clearing Limited was the fourth largest circulating shareholder, holding 24.33 million shares, unchanged from the previous period [3]

Company Overview - RuiZhi Pharmaceutical is located in Guangzhou, Guangdong Province, and was established on January 26, 2000. The company was listed on December 22, 2010. Its main business involves pharmaceutical research and production outsourcing services, micro-ecological nutrition, and micro-ecological medical services [1][2]. Financial Performance - For the first half of 2025, RuiZhi Pharmaceutical achieved operating revenue of 534 million yuan, representing a year-on-year growth of 14.75%. The net profit attributable to the parent company was 25.38 million yuan, showing a significant increase of 140.35% year-on-year [2]. - Since its A-share listing, RuiZhi Pharmaceutical has distributed a total of 180 million yuan in cash dividends, with no dividends paid in the last three years [3]. Stock Performance - As of September 15, RuiZhi Pharmaceutical's stock price increased by 2.01%, reaching 13.67 yuan per share, with a total market capitalization of 6.807 billion yuan. The stock has risen by 112.93% year-to-date [1]. - The stock has experienced a slight decline of 0.58% over the past five trading days, but has increased by 1.79% over the past 20 days and by 24.16% over the past 60 days [1]. Shareholder Information - As of August 8, the number of shareholders for RuiZhi Pharmaceutical was 52,500, a decrease of 18.89% from the previous period. The average number of circulating shares per person increased by 23.28% to 9,038 shares [2]. - As of June 30, 2025, Hong Kong Central Clearing Limited was the fourth-largest circulating shareholder, holding 24.33 million shares, with no change in the number of shares held compared to the previous period [3]. Market Position - RuiZhi Pharmaceutical operates within the pharmaceutical and biotechnology sector, specifically in medical services and medical research outsourcing. The company is involved in various concept sectors, including Alzheimer's, biopharmaceuticals, peptide drugs, innovative drugs, and cancer treatment [2].